Literature DB >> 11530188

Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.

D F Smee1, K W Bailey, M H Wong, R W Sidwell.   

Abstract

Intranasal infection of BALB/c mice with the WR strain of vaccinia virus leads to pneumonia, profound weight loss, and death. Although the major sites of virus replication are in the lungs and nasal tissue, dissemination of the virus to other visceral organs and brain occurs via the blood. In this report the effects of cidofovir on the pathogenesis of the infection was studied. Mice were infected intranasally with virus followed 1 day later by a single intraperitoneal treatment with cidofovir (100 mg/kg) or placebo. Placebo-treated mice were dead by day 8, whereas all cidofovir-treated animals survived through 21 days. Cidofovir treatment did not prevent profound weight loss from occurring during the acute phase of the infection, but the mice gained weight quickly after the 8th day. Significantly higher arterial oxygen saturation levels, as determined by pulse oximetry, were seen in cidofovir-treated animals compared to placebos on days 4-7. Cidofovir treatment markedly improved lung consolidation scores and prevented lung weights from increasing during the infection. Virus titers in lungs and nasal tissue were high starting from the first day of the infection, whereas the titers in liver, spleen, brain, and blood was low for 3 days then markedly rose between days 4 and 6. Lung and nasal virus titers were reduced 10-30-fold by cidofovir treatment on days 2, 4 and 6. Virus titers in the other tissues and blood at their peak (day 6) were 30- to >1000-fold less than in tissues of placebos. These results illustrate the ability of a single cidofovir treatment to control the pathogenesis of an acute lethal infection in various tissues during the vaccinia virus infection in mice.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11530188     DOI: 10.1016/s0166-3542(01)00159-0

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  36 in total

1.  Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

Authors:  Zhaochun Chen; Patricia Earl; Jeffrey Americo; Inger Damon; Scott K Smith; Yi-Hua Zhou; Fujuan Yu; Andrew Sebrell; Suzanne Emerson; Gary Cohen; Roselyn J Eisenberg; Juraj Svitel; Peter Schuck; William Satterfield; Bernard Moss; Robert Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-25       Impact factor: 11.205

2.  Gamma interferon and perforin control the strength, but not the hierarchy, of immunodominance of an antiviral CD8+ T cell response.

Authors:  Sanda Remakus; Luis J Sigal
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

3.  Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures.

Authors:  R Snoeck; A Holý; C Dewolf-Peeters; J Van Den Oord; E De Clercq; G Andrei
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.

Authors:  James J McSharry; Mark R Deziel; Kris Zager; Qingmei Weng; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

Review 5.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

6.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

Review 7.  Smallpox vaccines for biodefense.

Authors:  Richard B Kennedy; Inna Ovsyannikova; Gregory A Poland
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

8.  Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.

Authors:  Debra C Quenelle; Deborah J Collins; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Aerosolized cidofovir is retained in the respiratory tract and protects mice against intranasal cowpox virus challenge.

Authors:  Chad J Roy; Robert Baker; Kenneth Washburn; Mike Bray
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.

Authors:  Cheryl X Zhang; Christian Sauder; Tahir Malik; Steven A Rubin
Journal:  Biologicals       Date:  2009-11-06       Impact factor: 1.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.